New drug trial aims to control teen brain tumors while monitoring growth

NCT ID NCT07286292

Summary

This study is testing a drug called vorasidenib in teenagers (ages 12 to under 18) who have a specific type of slow-growing brain tumor. The main goals are to see if the drug is safe, what side effects it causes, and how it might affect the teens' normal growth and development during puberty. Researchers will also track if the drug helps control the tumor.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA WITH AN IDH1 OR IDH2 MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.